TY - JOUR T1 - Optimal glucocorticoid dose and the effects on mortality, length of stay, and readmission rates in patients diagnosed with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) JF - Journal of Investigative Medicine JO - J Investig Med SP - 1161 LP - 1164 DO - 10.1136/jim-2019-001105 VL - 67 IS - 8 AU - Asim Kichloo AU - Michael Aljadah AU - Navya Vipparla AU - Farah Wani Y1 - 2019/12/01 UR - http://hw-f5-jim.highwire.org/content/67/8/1161.abstract N2 - The burden of acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is staggering on a national and global level. Yet, surprisingly, there is a profound lack of treatment standardization with glucocorticoids in the treatment of AECOPD. In this review, we bring attention to specific literature that use a cut-off of 60 mg prednisone equivalent per day when distinguishing between high-dose and low-dose glucocorticoid treatment. We hope this review encourages future research to begin incrementally lowering the cut-off dose of 60 mg to discover if mortality, length of hospital stays, and readmission rates change between high-dose and low-dose glucocorticoid treatment. The final hope would be to establish an optimal glucocorticoid dose to treat AECOPD and eliminate treatment ambiguity. ER -